Type of security: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
The data is delayed by 15 minutes.
Description: bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing gene therapies for severe genetic and orphan diseases. The company?s advanced product candidate is Lenti-D, which is in phase II/III studies for the treatment of childhood cerebral adrenoleukodystrophy, a rare, hereditary neurological disorder affecting young boys; and LentiGlobin that is in phase I/II studies for the treatment of beta-thalassemia major and severe sickle cell disease in France, as well as a second phase I/II studies with LentiGlobin for the treatment of beta-thalassemia major in the United States. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||-7.22||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||0.14%||Sales Growth - Q/Q||-0.66%||P/E||-15.06|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-11.78%||ROE||-13.25%||ROI|
|Current Ratio||8.11||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.09|
|Gross Margin||Operating Margin||-294.47%||Net Profit Margin||-247.3%||Dividend Payout Ratio|
|Cash From Financing Activities||2.46 M||Cash From Investing Activities||-192.98 M||Cash From Operating Activities||-24.16 M||Gross Profit|
|Net Profit||-24.79 M||Operating Profit||-24.93 M||Total Assets||533.82 M||Total Current Assets||340.84 M|
|Total Current Liabilities||42.01 M||Total Debt||Total Liabilities||59.32 M||Total Revenue||6.34 M|
|High 52 week||176||Low 52 week||91.25||Last close||125.23||Last change||0.71%|
|RSI||31.32||Average true range||5.21||Beta||1.76||Volume||513.89 K|
|Simple moving average 20 days||-5.49%||Simple moving average 50 days||-1.71%||Simple moving average 200 days||-3.24%|
|Performance Week||4.12%||Performance Month||-6.53%||Performance Quart||-5.99%||Performance Half||-4.22%|
|Performance Year||-20.34%||Performance Year-to-date||26.24%||Volatility daily||2.51%||Volatility weekly||5.62%|
|Volatility monthly||11.51%||Volatility yearly||39.88%||Relative Volume||135.56%||Average Volume||563.09 K|
|New High||New Low|
2019-09-19 09:57:05 | Is There An Opportunity With bluebird bio, Inc.'s NASDAQ:BLUE 48% Undervaluation?
2019-09-18 09:25:00 | bluebird bio Presents Updated Data from Phase 2/3 Clinical Study of Lenti-D™ Gene Therapy for Cerebral Adrenoleukodystrophy CALD at the 13th European Pediatric Neurology Society EPNS Congress
2019-09-09 13:33:00 | Here's Why bluebird bio Fell 21.3% in August
2019-09-06 11:53:03 | FDA Grants Priority Review to Global Blood's SCD Candidate
2019-08-31 09:31:01 | Bluebird BLUE Down 19.4% Since Last Earnings Report: Can It Rebound?
2019-08-22 16:05:00 | bluebird bio Announces Investor Events in September
2019-08-22 02:18:27 | Massachusetts-based biotech company opens office in Eastlake neighborhood Photos
2019-08-16 06:20:45 | Gene therapies to test FDA's approach to regulating drugs after launch, experts say
2019-08-12 16:16:47 | Why This Biotech's $1.8 Million Gene Therapy Could Be A 'Slow Mover'
2019-08-12 10:30:00 | Bluebird Bio Stock Down as Analyst Raises Worries About Zynteglo Launch
2019-08-12 07:38:00 | Bluebird Bio Drops Following William Blair Downgrade
2019-08-08 10:25:53 | Did bluebird bio, Inc. NASDAQ:BLUE Insiders Sell Shares?
2019-08-07 17:30:00 | bluebird bio Prepares for Launch
2019-08-02 11:12:03 | bluebird's BLUE Loss Wider Than Expected, Revenues Beat
2019-08-01 19:45:11 | Bluebird Bio BLUE Reports Q2 Loss, Tops Revenue Estimates
2019-07-15 14:46:29 | Biotech investors Wellington, RA Capital’s new funds top $700 million
2019-07-10 05:43:59 | JP Morgan: 2 Gene Therapy Stocks to Buy Now
2019-07-09 13:58:30 | 5 Immunotherapy Stocks to Keep a Close Eye On
2019-07-07 12:13:00 | Is bluebird bio a Buy?
2019-07-02 11:53:53 | Marshall Wace’s Return, AUM, and Holdings Part II
2019-06-21 08:00:00 | Where Will bluebird bio Be in 1 Year?
2019-06-18 16:14:26 | Why This Biotech's Approved Gene Therapy Won't Launch Until 2020
2019-06-18 08:04:57 | See what the IHS Markit Score report has to say about bluebird bio Inc.
2019-06-17 19:17:06 | Is bluebird bio Inc BLUE A Good Stock To Buy?
2019-06-15 17:00:00 | Is $1.8 Million for bluebird bio's New Gene Therapy Ridiculous?
2019-06-14 16:00:00 | Bluebird Bio’s Gene Therapy Is $1.8 Million Per Patient. The Stock Is Falling.
2019-06-14 08:54:57 | Bluebird prices gene therapy in Europe at $1.8M over 5 years
2019-06-14 05:31:00 | bluebird bio Presents Long-Term Efficacy and Safety Data from Clinical Studies of LentiGlobin® Gene Therapy for Transfusion-Dependent ?-Thalassemia TDT at 24th European Hematology Association EHA Congress
2019-06-13 22:35:59 | Bluebird Bio prices gene therapy at nearly $1.8m
2019-06-13 21:08:21 | Chicago biotech sues Third Rock, bluebird bio CEO over gene therapy license
2019-06-12 12:14:58 | bluebird bio NASDAQ:BLUE Shareholders Have Enjoyed An Impressive 223% Share Price Gain
2019-06-10 08:06:59 | See what the IHS Markit Score report has to say about bluebird bio Inc.
2019-06-06 09:17:39 | Life sciences VC firm Third Rock raises $770M in its largest round ever
2019-06-04 16:16:08 | bluebird's Zynteglo Gets EU Conditional Marketing Approval
2019-06-04 15:31:00 | It's Official: bluebird bio Gets a Green Light for Game-Changing Gene Therapy
2019-06-03 09:25:00 | bluebird bio Announces EU Conditional Marketing Authorization for ZYNTEGLO™ autologous CD34+ cells encoding ?A-T87Q-globin gene Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent ?-Thalassemia Who Do Not Have ?0/?0 Genotype
2019-06-01 09:31:01 | Why Is Bluebird BLUE Down 15.1% Since Last Earnings Report?
2019-06-01 08:07:02 | See what the IHS Markit Score report has to say about bluebird bio Inc.
2019-05-31 08:00:00 | bluebird bio Announces Investor Events in June
2019-05-30 14:34:07 | Save the Date: 11 Biotech Stocks to Put on Your Radar
2019-05-28 08:07:01 | See what the IHS Markit Score report has to say about bluebird bio Inc.
2019-05-25 12:30:42 | Marshall Wace’s Latest Moves
2019-05-19 07:00:00 | Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big
2019-05-16 09:12:00 | bluebird bio to Present New Data from Clinical Studies of LentiGlobin™ Gene Therapy for Transfusion-Dependent ?-thalassemia TDT and LentiGlobin Gene Therapy for Sickle Cell Disease SCD at the 24th EHA Congress
2019-05-15 14:10:36 | Bluebird Bio's Near-Term Product Launches Pose Risks, Wedbush Says In Downgrade
2019-05-15 10:49:00 | Bluebird Bio’s Pricing Plan Worries One Biotech Analyst. Here’s Why.